Join Fulcrum Therapeutics for a virtual investor event featuring company leadership and key opinion leaders (KOLs) Dr. Sheinei Alan (Director, Inova Adult Sickle Cell Program & Assistant Professor, UVA School of Medicine Inova Campus) and Dr. Martin Steinberg (Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian & Avedisian School of Medicine), to review new data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD), which will be presented at the 67th American Society of Hematology (ASH) Annual Meeting.

The event will provide initial clinical data from the 20 mg dose cohort. These data will further characterize pociredir’s potential as a disease-modifying therapy for sickle cell disease. Pociredir is a novel oral once-daily fetal hemoglobin inducer for the treatment of sickle cell disease.

A live question and answer session will follow the formal presentation.